Selected research
Industry Research
Adipose Derived Stem Cell Therapy Industry Research Report 2026
Market perspective
The global Adipose Derived Stem Cell Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Adipose Derived Stem Cell Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Adipose Derived Stem Cell Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Adipose Derived Stem Cell Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Adipose Derived Stem Cell Therapy include Lonza, Tissue Genesis, Pluristem Therapeutics, Pluristem Therapeutics, Mesoblast, iXCells Biotechnologies, Intrexon, Cytori Therapeutics and Cyagen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Adipose Derived Stem Cell Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Adipose Derived Stem Cell Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Adipose Derived Stem Cell Therapy Market by Company
Lonza
Tissue Genesis
Pluristem Therapeutics
Pluristem Therapeutics
Mesoblast
iXCells Biotechnologies
Intrexon
Cytori Therapeutics
Cyagen
Corestem
Celltex Therapeutics Corporation
Cellleris
Celgene Corporation
BioRestorative Therapies
Antria
AlloCure
Adipose Derived Stem Cell Therapy Segment by Type
Autologous Stem Cells
Allogeneic Stem Cells
Adipose Derived Stem Cell Therapy Segment by Application
Therapeutic Application
Research Application
Adipose Derived Stem Cell Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adipose Derived Stem Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Adipose Derived Stem Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adipose Derived Stem Cell Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Adipose Derived Stem Cell Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Autologous Stem Cells
- Allogeneic Stem Cells
Applications
- Therapeutic Application
- Research Application
Companies covered
- Lonza
- Tissue Genesis
- Pluristem Therapeutics
- Pluristem Therapeutics
- Mesoblast
- iXCells Biotechnologies
- Intrexon
- Cytori Therapeutics
- Cyagen
- Corestem
- Celltex Therapeutics Corporation
- Cellleris
- Celgene Corporation
- BioRestorative Therapies
- Antria
- AlloCure
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Adipose Derived Stem Cell Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Autologous Stem Cells
- 2.2.3 Allogeneic Stem Cells
- 2.3 Adipose Derived Stem Cell Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Therapeutic Application
- 2.3.3 Research Application
- 2.4 Assumptions and Limitations
3 Adipose Derived Stem Cell Therapy Breakdown Data by Type
- 3.1 Global Adipose Derived Stem Cell Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Adipose Derived Stem Cell Therapy Forecasted Market Size by Type (2027-2032)
4 Adipose Derived Stem Cell Therapy Breakdown Data by Application
- 4.1 Global Adipose Derived Stem Cell Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Adipose Derived Stem Cell Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Adipose Derived Stem Cell Therapy Market Perspective (2021-2032)
- 5.2 Global Adipose Derived Stem Cell Therapy Growth Trends by Region
- 5.2.1 Global Adipose Derived Stem Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Adipose Derived Stem Cell Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Adipose Derived Stem Cell Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Adipose Derived Stem Cell Therapy Market Dynamics
- 5.3.1 Adipose Derived Stem Cell Therapy Industry Trends
- 5.3.2 Adipose Derived Stem Cell Therapy Market Drivers
- 5.3.3 Adipose Derived Stem Cell Therapy Market Challenges
- 5.3.4 Adipose Derived Stem Cell Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Adipose Derived Stem Cell Therapy Players by Revenue
- 6.1.1 Global Top Adipose Derived Stem Cell Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Adipose Derived Stem Cell Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Adipose Derived Stem Cell Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Adipose Derived Stem Cell Therapy Head Office and Area Served
- 6.4 Global Adipose Derived Stem Cell Therapy Players, Product Type & Application
- 6.5 Global Adipose Derived Stem Cell Therapy Manufacturers Established Date
- 6.6 Global Adipose Derived Stem Cell Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Adipose Derived Stem Cell Therapy Market Size (2021-2032)
- 7.2 North America Adipose Derived Stem Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Adipose Derived Stem Cell Therapy Market Size by Country (2021-2026)
- 7.4 North America Adipose Derived Stem Cell Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Adipose Derived Stem Cell Therapy Market Size (2021-2032)
- 8.2 Europe Adipose Derived Stem Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Adipose Derived Stem Cell Therapy Market Size by Country (2021-2026)
- 8.4 Europe Adipose Derived Stem Cell Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Adipose Derived Stem Cell Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Adipose Derived Stem Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Adipose Derived Stem Cell Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Adipose Derived Stem Cell Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Adipose Derived Stem Cell Therapy Market Size (2021-2032)
- 10.2 South America Adipose Derived Stem Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Adipose Derived Stem Cell Therapy Market Size by Country (2021-2026)
- 10.4 South America Adipose Derived Stem Cell Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Adipose Derived Stem Cell Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Adipose Derived Stem Cell Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Adipose Derived Stem Cell Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Adipose Derived Stem Cell Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Lonza
- 12.1.1 Lonza Company Information
- 12.1.2 Lonza Business Overview
- 12.1.3 Lonza Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.1.4 Lonza Adipose Derived Stem Cell Therapy Product Portfolio
- 12.1.5 Lonza Recent Developments
- 12.2 Tissue Genesis
- 12.2.1 Tissue Genesis Company Information
- 12.2.2 Tissue Genesis Business Overview
- 12.2.3 Tissue Genesis Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.2.4 Tissue Genesis Adipose Derived Stem Cell Therapy Product Portfolio
- 12.2.5 Tissue Genesis Recent Developments
- 12.3 Pluristem Therapeutics
- 12.3.1 Pluristem Therapeutics Company Information
- 12.3.2 Pluristem Therapeutics Business Overview
- 12.3.3 Pluristem Therapeutics Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.3.4 Pluristem Therapeutics Adipose Derived Stem Cell Therapy Product Portfolio
- 12.3.5 Pluristem Therapeutics Recent Developments
- 12.4 Pluristem Therapeutics
- 12.4.1 Pluristem Therapeutics Company Information
- 12.4.2 Pluristem Therapeutics Business Overview
- 12.4.3 Pluristem Therapeutics Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.4.4 Pluristem Therapeutics Adipose Derived Stem Cell Therapy Product Portfolio
- 12.4.5 Pluristem Therapeutics Recent Developments
- 12.5 Mesoblast
- 12.5.1 Mesoblast Company Information
- 12.5.2 Mesoblast Business Overview
- 12.5.3 Mesoblast Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.5.4 Mesoblast Adipose Derived Stem Cell Therapy Product Portfolio
- 12.5.5 Mesoblast Recent Developments
- 12.6 iXCells Biotechnologies
- 12.6.1 iXCells Biotechnologies Company Information
- 12.6.2 iXCells Biotechnologies Business Overview
- 12.6.3 iXCells Biotechnologies Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.6.4 iXCells Biotechnologies Adipose Derived Stem Cell Therapy Product Portfolio
- 12.6.5 iXCells Biotechnologies Recent Developments
- 12.7 Intrexon
- 12.7.1 Intrexon Company Information
- 12.7.2 Intrexon Business Overview
- 12.7.3 Intrexon Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.7.4 Intrexon Adipose Derived Stem Cell Therapy Product Portfolio
- 12.7.5 Intrexon Recent Developments
- 12.8 Cytori Therapeutics
- 12.8.1 Cytori Therapeutics Company Information
- 12.8.2 Cytori Therapeutics Business Overview
- 12.8.3 Cytori Therapeutics Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.8.4 Cytori Therapeutics Adipose Derived Stem Cell Therapy Product Portfolio
- 12.8.5 Cytori Therapeutics Recent Developments
- 12.9 Cyagen
- 12.9.1 Cyagen Company Information
- 12.9.2 Cyagen Business Overview
- 12.9.3 Cyagen Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.9.4 Cyagen Adipose Derived Stem Cell Therapy Product Portfolio
- 12.9.5 Cyagen Recent Developments
- 12.10 Corestem
- 12.10.1 Corestem Company Information
- 12.10.2 Corestem Business Overview
- 12.10.3 Corestem Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.10.4 Corestem Adipose Derived Stem Cell Therapy Product Portfolio
- 12.10.5 Corestem Recent Developments
- 12.11 Celltex Therapeutics Corporation
- 12.11.1 Celltex Therapeutics Corporation Company Information
- 12.11.2 Celltex Therapeutics Corporation Business Overview
- 12.11.3 Celltex Therapeutics Corporation Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.11.4 Celltex Therapeutics Corporation Adipose Derived Stem Cell Therapy Product Portfolio
- 12.11.5 Celltex Therapeutics Corporation Recent Developments
- 12.12 Cellleris
- 12.12.1 Cellleris Company Information
- 12.12.2 Cellleris Business Overview
- 12.12.3 Cellleris Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.12.4 Cellleris Adipose Derived Stem Cell Therapy Product Portfolio
- 12.12.5 Cellleris Recent Developments
- 12.13 Celgene Corporation
- 12.13.1 Celgene Corporation Company Information
- 12.13.2 Celgene Corporation Business Overview
- 12.13.3 Celgene Corporation Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.13.4 Celgene Corporation Adipose Derived Stem Cell Therapy Product Portfolio
- 12.13.5 Celgene Corporation Recent Developments
- 12.14 BioRestorative Therapies
- 12.14.1 BioRestorative Therapies Company Information
- 12.14.2 BioRestorative Therapies Business Overview
- 12.14.3 BioRestorative Therapies Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.14.4 BioRestorative Therapies Adipose Derived Stem Cell Therapy Product Portfolio
- 12.14.5 BioRestorative Therapies Recent Developments
- 12.15 Antria
- 12.15.1 Antria Company Information
- 12.15.2 Antria Business Overview
- 12.15.3 Antria Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.15.4 Antria Adipose Derived Stem Cell Therapy Product Portfolio
- 12.15.5 Antria Recent Developments
- 12.16 AlloCure
- 12.16.1 AlloCure Company Information
- 12.16.2 AlloCure Business Overview
- 12.16.3 AlloCure Revenue in Adipose Derived Stem Cell Therapy Business (2021-2026)
- 12.16.4 AlloCure Adipose Derived Stem Cell Therapy Product Portfolio
- 12.16.5 AlloCure Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst